bd 1047 has been researched along with oxidopamine in 1 studies
| Studies (bd 1047) | Trials (bd 1047) | Recent Studies (post-2010) (bd 1047) | Studies (oxidopamine) | Trials (oxidopamine) | Recent Studies (post-2010) (oxidopamine) |
|---|---|---|---|---|---|
| 118 | 0 | 54 | 8,630 | 6 | 2,407 |
| Protein | Taxonomy | bd 1047 (IC50) | oxidopamine (IC50) |
|---|---|---|---|
| Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) | 8 | |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | 0.779 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kadnikov, IA; Seredenin, SB; Voronin, MV; Voronkov, DN | 1 |
1 other study(ies) available for bd 1047 and oxidopamine
| Article | Year |
|---|---|
Chaperone Sigma1R mediates the neuroprotective action of afobazole in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Benzimidazoles; Corpus Striatum; Disease Models, Animal; Dopamine; Ethylenediamines; Male; Mice; Mice, Inbred ICR; Morpholines; Neurons; Neuroprotection; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Receptors, sigma; Rotarod Performance Test; Sigma-1 Receptor; Substantia Nigra | 2019 |